CompletedPhase 2NCT01653028
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Studying Myxofibrosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Mark DicksonAlliance for Clinical Trials in Oncology
- Intervention
- Alisertib(drug)
- Enrollment
- 72 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012
Study locations (30)
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- The Medical Center of Aurora, Aurora, Colorado, United States
- Boulder Community Hospital, Boulder, Colorado, United States
- Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States
- Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States
- Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States
- Porter Adventist Hospital, Denver, Colorado, United States
- Colorado Blood Cancer Institute, Denver, Colorado, United States
- Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States
- Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States
- SCL Health Saint Joseph Hospital, Denver, Colorado, United States
- Rocky Mountain Cancer Centers-Rose, Denver, Colorado, United States
- Rose Medical Center, Denver, Colorado, United States
- Colorado Cancer Research Program NCORP, Denver, Colorado, United States
- Mercy Medical Center, Durango, Colorado, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01653028 on ClinicalTrials.gov